Eloxx Pharmaceuticals Inc. Stock News

New Oriental Education & Technology Group Inc. (NYSE:EDU) with the stream of 4.07% also noticed, India Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) encountered a rapid change of -5.41% in the last hour The post Top RSI Trades for the day: New Oriental Education & Technology Group Inc. (NYSE:EDU), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) appeared first on Stocks Equity .

Analysts expect that Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) will announce ($0.12) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Eloxx Pharmaceuticals earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.11). Eloxx Pharmaceuticals posted earnings per share of ($0.15) in the same []

State Street Corp reduced its holdings in shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) by 56.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 189,203 shares of the companys stock after selling 248,516 shares during the quarter. State Street Corps holdings in []

In the last trading session, 1.24 million Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) shares changed hands as the companys beta touched 2.32. With the companys per share price at $0.62 changed hands at -$0.11 or -14.31% during last session, the market valuation stood at $62.69M. ELOXs last price was a discount, traded about -991.94% off its 52-week An Overview Of Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Read More »

Charles Schwab Investment Management Inc. boosted its position in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) by 125.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 367,062 shares of the companys stock after purchasing an additional 204,261 shares during the quarter. Charles Schwab Investment []

H.C. Wainwright lowered the price target on Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) to $1 from $2 and

H.C. Wainwright lowered the price target on Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) to $1 from $2 and reiterated a Neutral rating. Analyst Andrew Fein says the ELX-02 top-line data "raises more q

Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) posted topline results from the monotherapy arms of its Phase 2 trial of ELX-02 in Class 1 cystic fibrosis patients with at least one G542X nonsense allele mutation. Eloxx delivered one-week ELX-02 data on 12 people with a G542X nonsense mutation who received ELX-02 at 1.5 mg/kg/day. Sweat chloride, a biomarker of cystic fibrosis, Full story available on Benzinga.com

ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity

Eloxx Pharmaceuticals (NASDAQ:ELOX) had its price objective trimmed by HC Wainwright from $3.00 to $2.00 in a research note published on Thursday morning, The Fly reports. The brokerage currently has a neutral rating on the stock. Separately, Zacks Investment Research upgraded Eloxx Pharmaceuticals from a sell rating to a hold rating in a research report []

Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights

The stock price of Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) significantly increased today. This is why it happened.

BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021

Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF)